SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Human & Experimental Toxicology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Hubert, M.
Right arrow Articles by Lison, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hubert, M.
Right arrow Articles by Lison, D.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*PYRIDOSTIGMINE BROMIDE
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Study of muscular effects of short-term pyridostigmine treatment in resting and exercising rats

Michel Hubert

AsIAT, Laboratory of Medical Toxicology, Vilvoorde

Dominique Lison

AsIAT, Laboratory of Medical Toxicology, Vilvoorde, Catholic University of Louvain, Industrial Toxicology and Occupational Medicine Unit, Brussels, Belgium

1. Pyridostigmine (PYR) pretreatment is used by the mili tary to obtain 20—30% whole blood acetylcholinesterase (AChE) inhibition in order to enhance the effectiveness of the standard therapeutic regimen for poisoning by an organophosphate anticholinesterase agent. The present study was undertaken to investigate in a rat model the potential muscle damage produced by this pretreatment when given alone or combined with physical exercise.

2. Grip strength and biochemical measurements, i.e. serum creatine phosphokinase (CPK) activity and creatine urinary excretion rate, together with histological studies, were performed in resting animals during a period of 14 days of PYR administration in a dose producing 20-30% whole blood acetylcholinesterase inhibition. No evidence was found of a deleterious effect of this treatment on the skeletal muscle.

3. In contrast, following physical exercise, the same treat ment significantly exacerbated the biochemical changes reflecting a loss of integrity in skeletal muscles, namely, increased CPK and urinary creatine excretion rate. The significance of this observation remains to be clarified.

Key Words: pyridostigmine • skeletal muscle • exercise • crea tine • creatine phosphokinase

Human & Experimental Toxicology, Vol. 14, No. 1, 49-54 (1995)
DOI: 10.1177/096032719501400110
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 NeurologyHome page
A. Rostedt and E. Stalberg
Joint pain and hyperalgesia due to pyridostigmine bromide in a patient with myasthenia gravis
Neurology, March 9, 2004; 62(5): 835 - 836.
[Full Text] [PDF]


Advertisement